Poster Presentation (Poster No.: P094) Positive Phase 2 Results of Orelabrutinib in Patients with Relapsing-Remitting Multiple Sclerosis Orelabrutinib was shown to be highly effective for the ...

The US regulator has placed oral BTK inhibitor orelabrutinib on partial clinical hold, meaning new patients cannot be enrolled into clinical trials and patients treated with the drug for 70 days ...

Revenue of Orelabrutinib increased by 49.1% to RMB 1,000.4 million 1 in 2024, mainly driven by rapid growth of marginal zone lymphoma (MZL) indication and strong commercial execution. Total ...

InnoCare gets $125 million upfront in return for sharing rights to orelabrutinib, an orally-active BTK drug that is able to cross the blood-brain barrier and penetrate the central nervous system.